5 Small Drug Stocks to Buy as the Industry Shows Some Recovery

IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622244d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results – Raises full-year 2026 LINZESS ® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 bi

Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pr.htm EX-99.1 Document Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 p atients now on therapy Advancement of rare ki

Ironwood Pharmaceuticals (IRWD) appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, effective July 20, 2026, replacing retiring Dr. Michael Shetzline, who will advise during transition. IRWD said its confirmatory Phase 3 STARS-2 trial of apraglutide for SBS-IF began in June and is actively recruiting. IRWD shares last traded at $4.08, down 3.09%.

Plus Therapeutics (NASDAQ:PSTV) said its CNSide Diagnostics unit received College of American Pathologists (CAP) accreditation for its CNSide CSF assay platform. The Houston lab passed an on-site CAP inspection covering protocols, documentation, quality control, staff, equipment, and management. The company said accreditation may support payer coverage, reimbursement talks, and faster commercial expansion; shares rose 8.7% to $5.89.

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.